# **Impact of the admitting ward on care quality and outcomes in non-ST-segment elevation myocardial infarction (NSTEMI): insights from a national registry**

Saadiq M Moledina1, Ahmad Shoaib1, Louise Y. Sun2, Phyo K. Myint 3, Rafail A Kotronias4, Benoy N Shah5, Chris P Gale6, Hude Quan7, Rodrigo Bagur1, Mamas A Mamas1

1. Keele Cardiovascular Research Group, Centre for Prognosis Research, Institute for Primary Care and Health Sciences, Keele University, United Kingdom (UK)
2. Division of Cardiac Anesthesiology, University of Ottawa Heart Institute, Ottawa, Ontario, Canada
3. Institute of Applied Health Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen AB25 2ZD, UK
4. Division of Cardiovascular Medicine, BHF Centre of Research Excellence, University of Oxford, Oxford, UK.
5. Department of Cardiology, Wessex Cardiac Centre, University Hospital Southampton, Southampton, UK
6. Leeds Institute for Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK
7. Centre for Health Informatics, University of Calgary, Calgary, Alberta, Canada

**Corresponding author:**

Prof. Mamas A. Mamas

Keele Cardiovascular Research Group,

Centre for Prognosis Research,

Keele University, Stoke-on-Trent, UK.

E-mail: mamasmamas1@yahoo.co.uk

**Tel:** +44 1782 671654 **Fax:** +44 1782 734719

Manuscript word count: 3551

Abstract word count: 242

**Key words**: NSTEMI, Ward, CCU, Mortality

### **Acknowledgements**

None

### **Funding**

### None

### **Conflict of interest:**

Prof. Gale reports personal fees from AstraZeneca, personal fees from Amgen, personal fees from Bayer, grants from BMS, personal fees from Boehrinher-Ingelheim, personal fees from Daiichi Sankyo, personal fees from Vifor Pharma, grants from Abbott, personal fees from Menarini, personal fees from Wondr Medical, personal fees from Raisio Group, grants from British Heart Foundation, grants from NIHR, grant from  
Horizon 2020, personal fees from Oxford University Press, grants from ESC, outside the submitted work.

No other conflicts declared

### **Data Availability**

The authors do not have authorization to share the data, but it can be accessed through contacting the National Institute for Cardiovascular Outcomes Research (NICOR) upon approval.

### **Ethics:**

Secondary use of anonymised MINAP dataset for research purposes is authorised under NHS research governance arrangements and further supported under section 251 of NHS act 2006 (NIGB: ECC1-06(d)/ 2011), which allows researchers to use patient information collected within the dataset for medical research without patient consent. Therefore, a formal ethical approval was not sought for this study.

**Abstract**

**Background:** Little is known about the association between the type of admission ward and quality of care and outcomes fornon-ST-segment elevation myocardial infarction (NSTEMI).

**Methods & Results:** We analysed data from 337,155 NSTEMI admissions between 2010-2017 in the United Kingdom (UK) Myocardial Ischaemia National Audit Project (MINAP) database. The cohort was dichotomised according to receipt of care either on a medical (n=142,876) or cardiac ward, inclusive of acute cardiac wards and cardiac care unit (n=194,279) on admission to hospital. Patients admitted to a cardiac ward were younger (median age 70y vs 75y, P<0.001), and less likely to be female (33% vs 40%, P<0.001). Independent factors associated with admission to a cardiac ward included ischaemic ECG changes (OR: 1.20, 95% CI: 1.18-1.23) and prior percutaneous coronary intervention (PCI) (OR: 1.19, 95% CI: 1.16-1.22). Patients admitted to a cardiac ward were more likely to receive optimal pharmacotherapy with statin (85% vs 81%, P<0.001) and dual antiplatelet therapy (DAPT) (91% vs 88%, P<0.001) on discharge, undergo invasive coronary angiography (78% vs 59%, P<0.001) and receive revascularisation in the form of PCI (52% vs 36%, P<0.001). Following multivariable logistic regression, the odds of in-hospital all-cause mortality (OR: 0.75, 95% CI: 0.70-0.81) and major adverse cardiovascular events (MACE) (OR: 0.84, 95% CI: 0.78-0.91) were lower in patients admitted to a cardiac ward.

**Conclusion:** Patients with NSTEMI admitted to a cardiac ward on admission were more likely to receive guideline directed management and had better clinical outcomes.

**Key words**: NSTEMI, Cardiac Ward, CCU, Mortality

**Introduction**

Non-ST-segment myocardial infarction (NSTEMI) represents a global health and economic burden1, with greater than 50,000 patients presenting yearly in England and Wales2. In many hospitals, these patients are triaged through the ‘acute medical take’ (admission from the emergency department to a medical team) and transferred to acute or general medical wards3, with limited provision to care for these patients on dedicated cardiac wards or on cardiac care units (CCU) where appropriate staffing, medical and nursing expertise is concentrated to manage patients during the acute phase of their ischaemic syndrome.

Whilst the impact of admitting patients to dedicated cardiac wards has been studied extensively for cardiovascular conditions such as acute heart failure4, 5, limited data exists on the care quality and outcomes for patients with NSTEMI admitted to these facilities. NSTEMI patients represent a heterogenous group with the high-risk subgroup having similar mortality rates to those presenting with ST-segment myocardial infarction (STEMI)6. Better understanding of the impact of the admitting ward for NSTEMI patients is necessary to guide future triaging on admission for these patients.

Using data from a large national registry in the UK, our study aims to look at the impact of admission ward on care quality and outcomes for patients with NSTEMI.

## **Methods**

**Study design:**

We used the Myocardial Ischaemia National Audit Project (MINAP), a prospective national registry of patients admitted to hospitals in the UK with an acute coronary syndrome. The MINAP dataset contains over 130 variables including baseline demographics and clinical characteristics, comorbid conditions, management strategies, pharmacotherapy, place of care, in-hospital clinical outcomes and diagnoses on discharge7-9. Data are submitted by each hospital’s clinical and clerical staff and approximately 90,000 pseudonymised records annually are uploaded to the National Institute for Cardiovascular Outcomes Research (NICOR) database.

**Study population:**

The sampling frame included patients admitted with NSTEMI to any of the 230 participating hospitals in England and Wales between 1st January 2010 to 31st March 2017. The discharge diagnosis of NSTEMI was determined by local clinicians according to presenting history, clinical examination, and the results of inpatient investigations in keeping with the consensus document of the Joint European Society of Cardiology and American College of Cardiology10.Missing records for mortality and admission ward were excluded from the analysis (Figure 1). The admission ward included patients directly admitted to a ward as well as patients admitted to a ward through the emergency department. The analytic cohort was dichotomised according to admission ward, group 1: not admitted to a cardiac ward (acute or general medical ward), group 2: admitted to a cardiac ward (acute cardiac ward and CCU).

**Quality indicators:**

We assessed the European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC) quality indicators (QI’s)11, looking specifically at the use of invasive coronary angiography (ICA) within 72 hours of admission; the assessment of left ventricular (LV) function; the use of fondaparinux or low molecular weight heparin (LMWH); and the prescription of P2Y12 inhibition, adequate dual antiplatelet therapy (DAPT) and statins on discharge. For patients with moderate and severe LV systolic dysfunction (LVSD), the use of angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) and beta blocker on discharge was also evaluated. The ESC QI for LVSD is defined as an ejection fraction (EF) less than or equal to 40%. The MINAP database do not have the same cut off points for LVSD, thus moderate (EF<49%) and severe LVSD (EF<30%) was used as a surrogate. Furthermore, MINAP does not record the specific type or dose of statin prescribed so ‘statin prescription’ was used as a surrogate for high-intensity statin.

**Outcomes**

Primary

Primary outcomes of interest were in-hospital all-cause mortality and major adverse cardiovascular events (MACE) (composite endpoint of in-patient all-cause mortality and reinfarction).

Secondary

Secondary outcomes of interest were in-hospital cardiac mortality (death attributable to myocardial ischaemia or infarction, heart failure (HF) and cardiac arrest of unknown cause) and major bleeding (a composite of gastrointestinal, retroperitoneal and intracranial haemorrhage).

**Statistical Analysis:**

Baseline characteristics and management strategies were summarised according to the admitting ward. Group wise comparisons were performed using Pearson’s chi squared, Student t-test or Mann-Whitney as appropriate. Gaussian continuous variables are expressed as mean ± standard deviation (SD); non-Gaussian continuous variables as median (IQR) and categorical variables as numbers and percentages. Where data were missing, this was assumed to be at random and we applied multiple imputations using chained equations (MICE) with ten imputations of the dataset. For imputation, we applied linear regression models for continuous data, multinomial logistic regression for ordinal data and logistic regression for binary data. For each binary outcome of interest, multivariable logistic regression analysis was applied on imputed datasets to estimate the risk of adverse outcomes between groups. Estimates were combined using Rubin’s rules12. Logistic regression models were fitted using maximum likelihood estimation and were adjusted for age, sex, ethnicity, heart rate, blood pressure, serum creatinine concentration on admission, family history of coronary artery disease (CAD), previous coronary artery bypass graft (CABG) surgery, ischaemic ECG changes, history of HF, LVSD, prior percutaneous coronary intervention (PCI), co-morbid conditions (history of diabetes mellitus, hypercholesterolaemia, angina, previous myocardial infarction, cerebrovascular accident, peripheral vascular disease, hypertension, smoking, asthma/COPD), pharmacotherapy (prescription of LMWH warfarin, un-fractionated heparin, GP IIb/IIIa inhibitor, intravenous nitrate, furosemide, aldosterone antagonist, fondaparinux, beta blockers, ACEi/ARB’s, aspirin, P2Y12 inhibitor, statins), cardiac arrest, procedures and investigations including ICA, PCI and CABG surgery during admission, type of centre according to catheter laboratory status, admission under a cardiologist in the first 24 hours, hospital and year.

**Subgroup Analysis:**

We further subdivided the patients who were admitted to a cardiac ward into those admitted to CCU and those who were not and looked at the quality of care and outcomes between the two groups.

**Factors associated with admission ward type:**

Multivariable logistic regression models were applied on the imputed data set to identify independent factors associated with ward type.

**Temporal and Geographical Changes:**

We evaluated all participating hospitals in our study to look at how the proportion of patients admitted to a cardiac ward varied according to the hospital they were treated at. Risk standardised mortality rates adjusted for patients’ demographics were calculated for each centre in our study. Subsequently, we undertook logistic regression to see if there was a correlation with the adjusted mortality rates and proportion of patients admitted to a cardiac ward. A secondary analysis with the same methodology was performed looking at patients admitted to a cardiac ward, with the exclusion of CCU patients. Furthermore, temporal changes in the proportions of patients with NSTEMI admitted according to the admission ward were evaluated.

All statistical analyses were performed with Stata 14.2 (College Station, Texas, USA) with data anonymized. All statistical analyses were two-tailed, and an alpha of 5% was used throughout, without multiplicity adjustment.

**Results**

**Baseline Characteristics:**

Between January 2010 to March 2017, there were 369,435 patients admitted to hospital in England and Wales with a diagnosis of NSTEMI. Applying relevant exclusion criteria (Figure 1) produced a study cohort consisting of 337,155 (9% excluded). Of these, 194,729 (58%) were admitted to a cardiac ward.

Differences in clinical characteristics at admission between the two groups are presented in Table 1. Patients admitted to a cardiac ward were more frequently younger (median age of 70y vs 75y), had previous PCI (16% vs 13%), hypercholesterolemia (40% vs 33%) and a family history of cardiovascular disease (31% vs 25%). Those admitted to a non-cardiac ward were more likely to have a higher GRACE risk score (81% vs 74%) and were more likely to be female (40% vs 33%). Furthermore, 12% of patients admitted to a cardiac ward were not admitted under a cardiologist during the first 24 hours of their admission; whereas 16% of patients admitted to a medical ward were admitted under the care of a cardiologist. Pharmacotherapy, management strategies & unadjusted crude clinical outcomes for both cohorts are presented in Table 2. Patients admitted to a cardiac ward more frequently received ICA (78% vs 59%), PCI (52% vs 36%) and CABG surgery (8% vs 7%) than those admitted to medical wards.

**Quality Indicators:**

Patients admitted to a cardiac ward more frequently received ICA within a 72-hour time frame from admission (74% vs 53%), adequate DAPT (91% vs 88%) or high intensity statins on discharge (85% vs 81%), and for those with LVSD received ACEi/ARB (86% vs 83%) or beta blockers (87% vs 82%) (Table 3).

**Clinical Outcomes:**

Patients admitted to a cardiac ward had lower unadjusted outcomes of mortality (2.7% vs 6.2%), cardiac mortality (2.2% vs 4.8%), major bleeding (1.3% vs 1.7%) and MACE (3.4% vs 6.9%). After adjustment for differences in baseline clinical and treatment characteristics on multivariate analysis, odds of all-cause mortality (OR: 0.75, 95% CI: 0.71-0.80), cardiac mortality (OR: 0.84, 95% CI: 0.78-0.91), MACE (OR: 0.85, 95% CI: 0.79-0.90) and major bleeding (OR: 0.76, 95% CI: 0.71-0.83) were all lower in patients admitted to a cardiac ward (Table 4).

**Factors associated with admission ward type:**

Independent factors of admission to a cardiac ward included cardiometabolic risk factors such as hypertension (OR: 1.04, 95% CI: 1.02-1.06), hypercholesterolemia (OR: 1.09, 95% CI: 1.07-1.12) and current smoking status (OR: 1.04, 95% CI: 1.02-1.07). Further predictors included previous PCI (OR: 1.19, 95% CI: 1.16-1.22) and CABG surgery (OR: 1.05, 95% CI: 1.01-1.09), ischaemic ECG changes (OR: 1.20, 95% CI: 1.18-1.23) as well as admission under the care of a cardiologist in the first 24 hours of admission (OR: 18.2, 95% CI: 17.9-18.6) (Table 5).

**Temporal and Geographical Changes:**

The proportion of patients with NSTEMI admitted to a cardiac ward increased from 52% in 2010 to 64% in 2017 (Supplement figure 1). Figure 2 demonstrates a statistically significant, albeit weak, inverse correlation between the mortality rate (adjusted for demographics) and admission to a cardiac ward (coefficient -0.021, 95% CI: -0.031 to –0.010, P<0.001), with an R2 of 0.06. Supplementary Figure 2 demonstrates the significant variability in the proportion of patients admitted to a cardiac ward depending on which hospital they were treated at varying from 0 to 100 %. Supplementary Figure 3 demonstrates the same trend between adjusted mortality rate and admission to a cardiac ward, with CCU patients excluded (coefficient -0.024, 95% CI: -0.038 to –0.010, P<0.001), with an R2 of 0.05.

**Subgroup analysis:**

In subgroup analysis, we studied characteristics, quality of care and outcomes in patients who were admitted to a cardiac ward (excluding CCU) to those admitted to CCU or medical wards. Patients admitted to a cardiac ward had similar characteristics to those admitted to CCU but were less likely to present as a cardiac arrest (1.3% vs 2.8%) and had lower in-hospital mortality (1.9% vs 3.1%), cardiac mortality (1.5% vs 2.6%) and MACE (2.6% vs 3.8%) compared to those admitted directly to CCU (Supplement tables 1 and 2). Patients admitted to a cardiac ward had similar rates of ICA within 72 hours (72% vs 74%), adequate P2Y12 inhibition on discharge (93% vs 93%), DAPT on discharge (91% vs 91%) to those presenting to CCU. They were more likely to be discharged with a high intensity statin (88% vs 84%) (Supplement table 3). Supplement table 4 shows the primary outcomes of mortality and MACE were all significantly lower in those admitted to a cardiac ward compared to those admitted to CCU (Mortality: OR: 0.80, 95% CI: 0.73-0.87, MACE: OR: 0.92, 95% CI:0.86-0.99, P=0.02) or medical wards (Mortality: OR: 0.64, 95% CI: 0.58-0.70, MACE: OR:0.80, 95% CI: 0.74-0.86).

Our key study findings are summarised in the central illustration figure (Figure 3).

**Discussion:**

The results of this analysis of greater than 300,000 patients within a centrally funded health care system shows differences in care exist for patients presenting with NSTEMI dependent on their admission ward independent of treating physician. Patients admitted to a cardiac ward tended to be younger, male, and more likely to receive optimal pharmacotherapy treatments, ICA and PCI with greater overall quality of care compared with those not admitted to a cardiac ward. Importantly, once differences in baseline characteristics and presentation were adjusted for, there were reduced odds of in-hospital mortality and MACE in patients admitted to a cardiac ward. Furthermore, we report significant differences in practice across the 230 hospitals in England and Wales with wide variation in the proportion admitted to a cardiac ward. There was a significant, albeit weak, correlation between standardized mortality rates of the individual centres and the proportion of patients admitted to a cardiac ward.

Previous studies examining the impact of the admitting ward in AMI have several important limitations. The majority of studies have focused on the impact of the specialty of admitting physician, with the assumption that patients admitted under a cardiologist are treated on a cardiac ward and vice versa. Whilst STEMI patients are often directly taken to CCU or the catheter laboratory for revascularization, NSTEMI patients in the UK are admitted from the emergency department via the ‘acute medical take’3. Often, the admitting specialty of the physician and type of ward the patient is admitted to are not mutually exclusive, with some patients admitted to general medical wards under the care of a cardiologist or to acute cardiac wards/CCU under the care of general medical physician. Thus, a knowledge gap exists looking at the independent association of the admitting ward. Furthermore, prior studies have predominantly focused on the effects of the CCU and less on acute cardiac wards13-15. With the ‘sickest’ patients, often perceived as STEMI, getting admitted to CCU, there is limited data on outcomes for NSTEMI patients as well as the direct effects of cardiac wards, excluding CCU.

Our analysis demonstrates that significant sex-disparities exist, with women less likely to be admitted to a cardiac ward. This is consistent with findings from *Alfredsson et al*, who assessed 570 consecutive patients with NSTEMI, finding that whilst there were no significant differences in mortality, women were significantly less likely to be admitted to a coronary care unit15. Our previous work has shown that they were also less likely to be admitted under the care of a cardiologist within the first 24 hours of admission16. Patients admitted to a cardiac ward were significantly more likely to receive ICA and PCI than those admitted to medical wards. This may explain why women are less likely to receive invasive treatment for NSTEMI, and when they do are less likely to be offered it in line with guideline recommendations17, 18. Reassuringly, our study shows that race was not an independent predictor of admission to a cardiac ward. Prior studies have shown that ethnic minorities are disadvantaged in process of care for AMI19, 20. Having equitable access to the resource allocation with expert nursing, medical and allied health professionals aligned to caring for patients available on a cardiac ward is likely to facilitate better outcomes in this group.

Patients admitted to a cardiac ward were more likely to attain the ESC QIs for acute myocardial infarction, where attainment of these specific QIs has been shown to have an inverse association with 30-day mortality21. This was also evident in our subgroup analysis; cardiac ward patients (CCU patients excluded), as well as CCU patients independently were more likely to attain these QIs compared to patients on medical wards. The cause of this is likely a combination of increasingly being managed by cardiologists on cardiac wards as well as having the benefits of an integrated service of a specialist unit where the multidisciplinary team works cohesively together. *Jolis et al* found cardiologists were more likely than other physicians to treat patients with medications associated with improved survival, and have increased use of echocardiography, coronary angiography and revascularisation22, whilst *Langhorne et al* demonstrated that stroke patients who receive organised care in specialist units were more likely to be alive, independent and living at home one year after the stroke23. Furthermore, Birkhead et al found patients admitted under a cardiologist or to a cardiac ward (CCU included) were less likely to be treated with an invasive strategy compared to those not admitted under a cardiologist and on a medical ward respectively24.

Clinical outcomes for NSTEMI patients including mortality (all-cause and cardiac), major bleeding and MACE were reduced in patients admitted to a cardiac ward. Potential factors that may explain this include the medical and nursing staff dealing with large numbers of NSTEMI patients, thus being adept at recognising complications such as major bleeding, whilst also being able to identify inaccuracies with medications and suboptimal management in a timelier fashion. There are likely to be additional unmeasured confounders that would contribute to this. Differences in the use of ICA and revascularization procedures may have contributed to improved survival, however, the benefits would become more apparent after one year of follow up22. It is possible that differences in severity of illness have led to lower in-hospital morality and MACE in patients admitted to a cardiac ward. Our analysis shows that patients admitted to a medical ward tended to be older and have a higher GRACE-risk score on admission which is associated with greater in-hospital mortality25, 26.

Our subgroup analysis showed that the characteristics of patients admitted to a cardiac ward and CCU were similar, with the main difference being patients in CCU representing a ‘sicker’ cohort of patients as evidenced by a greater proportion presenting as a cardiac arrest or with a high GRACE risk score. The main structural differences of a CCU in comparison to a ‘general’ cardiac ward include increased nursing ratios, fewer patients and increased use of invasive monitoring equipment13, 14. It is likely their worse outcomes of in-hospital mortality and MACE compared to cardiac ward patients is largely driven by the more unwell cohort of patients and less by structural differences to ‘general’ cardiac wards. It is interesting to note that almost one in four patients admitted to CCU were not admitted under the care of a cardiologist. This is likely a reflection of how hospitals are set up in the UK with some smaller hospitals having the provision of a CCU, but not necessarily having cardiologist cover out of normal working hours27. The odds of in-hospital mortality and MACE were significantly lower in patients admitted to a cardiac ward compared to medical wards. Resource allocations with easier access to specialist care, provisions such as telemetry, frequent non-invasive monitoring and healthcare staff who routinely deal with acutely unwell NSTEMI patients are likely to be the key determinants as to why their outcomes are worse.

Given the vast disparities in quality of care and outcomes between the type of admitting ward, our study has clinical implications that would support changes in the practice of NSTEMI management in healthcare systems such as the UK. Whilst the proportion of patients being admitted to a cardiac ward has steadily increased from 2010 to 2017, more can be done. Currently there may not be capacity to accommodate all NSTEMI patients on cardiac wards due to limited beds and staff. However, setting the “gold standard” for NSTEMI patients as admission to a cardiac ward is likely to place increased prominence on the importance of admission ward to those responsible in the admitting pathway of these patients. Incorporating admission to a cardiac ward as an NSTEMI quality indicator, for example, may go some way to achieving this. Our previous work has shown that patients admitted directly under a cardiologist in the first 24 hours of care had better quality of care and outcomes compared to those who were not admitted under a cardiologist but reviewed by them during their admission16. Thus, having increased presence of cardiologists reviewing NSTEMI patients on medical wards is unlikely to solely bridge the gap in quality of care compared to those who were directly admitted to a cardiac ward. If there is not a provision to manage all NSTEMI patients on cardiac wards as it is a finite resource, our focus should look to concentrate patients who definitively require invasive management on cardiac wards to improve the timing of their revascularisation with efforts to provide further education for staff dealing with NSTEMI patients on medical wards. It is important to highlight that these decisions are complex where vast experience, in the form of either cardiologists or senior ward-based cardiology trained nurses would be most optimally placed to identify these patients28. Until such provisions are met that all patients with NSTEMI can be managed on a cardiac ward, the utilisation of cardiology trained nursing staff with triaging experience is likely to help select in a timelier fashion the patients who benefit most from an invasive strategy, particularly in hospitals in which cardiology consults are not available during weekends.

There are a number of strengths to this study. Our analysis represents the largest study to date that looks at differences in care quality and outcomes of NSTEMI patients by the specialty of the admitting ward. The MINAP database encapsulates an almost complete record of NSTEMI patients admitted in the UK and represents one of the largest national real-world databases of this cohort of patients in the world, including those that are high risk and have multiple comorbid illness, such that they are either not included or under-represented in clinical trials.

Despite these strengths, there are several important limitations common to observational studies of this type. The MINAP data collection shares the weakness of other national registries, including self-reporting of adverse events where there is no external validation of these. Although the MINAP dataset included important clinical and demographic variables of interest, there are limitations to data collected. For instance, the database does not capture frailty score or index, severity of coronary artery disease, contraindications to medications, or an exhaustive list of comorbid conditions. Nor does the database capture the type or dose of statin used. This is important as there is emerging evidence that this has a key role on in-hospital mortality outcomes29. Our data does not show the precise degree of involvement of cardiologists’ input to patients on different wards, nor does it show any data regarding transfer of patients from their admission ward. In addition, the MINAP database only records in-hospital clinical outcomes and it is possible that long term follow-up data may reveal further differences in the crude clinical outcomes of patients admitted to a cardiac ward vs those who were not. Finally, some cases of NSTEMI may have been misdiagnosed or misclassified as a type 2 myocardial infarction.

**Conclusion:**

Our study demonstrates that between 2010-2017, only 58% of patients diagnosed with NSTEMI were admitted to a cardiac ward. There is wide variation of practice amongst centres in England and Wales, and a significant correlation exists which shows the mortality rate for individual centres decreases as the proportion of patients admitted to a cardiac ward increases. Those admitted to a cardiac ward were more likely to attain the ESC ACVC QIs and had better outcomes of mortality, major bleeding and MACE, independent of admitting physicians.Whilst a randomised control trial may give more credence to our work, a significant opportunity exists to improve the management of NSTEMI patients by accelerating the proportion of NSTEMI patients admitted to a cardiac ward, subsequently improving the quality of care and outcomes in this cohort.

**References**

1. Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, Mossialos EA, Maggioni AP, Kazakiewicz D, May HT, De Smedt D, Flather M, Zuhlke L, Beltrame JF, Huculeci R, Tavazzi L, Hindricks G, Bax J, Casadei B, Achenbach S, Wright L and Vardas P. European Society of Cardiology: Cardiovascular Disease Statistics 2019. *Eur Heart J*. 2020;41:12-85.

2. Dondo TB, Hall M, Timmis AD, Yan AT, Batin PD, Oliver G, Alabas OA, Norman P, Deanfield JE, Bloor K, Hemingway H and Gale CP. Geographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study. *BMJ Open*. 2016;6:e011600.

3. Cramer H, Hughes J, Johnson R, Evans M, Deaton C, Timmis A, Hemingway H, Feder G and Featherstone K. 'Who does this patient belong to?' boundary work and the re/making of (NSTEMI) heart attack patients. *Sociol Health Illn*. 2018;40:1404-1429.

4. Ezekowitz JA, van Walraven C, McAlister FA, Armstrong PW and Kaul P. Impact of specialist follow-up in outpatients with congestive heart failure. *Cmaj*. 2005;172:189-94.

5. Parmar KR, Xiu PY, Chowdhury MR, Patel E and Cohen M. In-hospital treatment and outcomes of heart failure in specialist and non-specialist services: a retrospective cohort study in the elderly. *Open Heart*. 2015;2:e000095.

6. Montalescot G, Dallongeville J, Van Belle E, Rouanet S, Baulac C, Degrandsart A and Vicaut E. STEMI and NSTEMI: are they so different? 1 year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). *Eur Heart J*. 2007;28:1409-17.

7. Wilkinson C, Weston C, Timmis A, Quinn T, Keys A and Gale CP. The Myocardial Ischaemia National Audit Project (MINAP). *Eur Heart J Qual Care Clin Outcomes*. 2020;6:19-22.

8. Rashid M, Curzen N, Kinnaird T, Lawson CA, Myint PK, Kontopantelis E, Mohamed MO, Shoaib A, Gale CP, Timmis A and Mamas MA. Baseline risk, timing of invasive strategy and guideline compliance in NSTEMI: Nationwide analysis from MINAP. *International journal of cardiology*. 2020;301:7-13.

9. Moledina SM, Shoaib A, Weston C, Aktaa S, Gc Van Spall H, Kassam A, Kontopantelis E, Banerjee S, Rashid M, Gale CP and Mamas MA. Ethnic disparities in care and outcomes of non-ST-segment elevation myocardial infarction: a nationwide cohort study. *Eur Heart J Qual Care Clin Outcomes*. 2021.

10. Alpert JS, Thygesen K, Antman E and Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *J Am Coll Cardiol*. 2000;36:959-69.

11. Gale CP LP. Non-ST-Segment Elevation Myocardial Infarction (NSTEMI) Registry. 2020;2021.

12. Rubin DB. Multiple Imputation After 18+ Years. *Journal of the American Statistical Association*. 1996;91:473-489.

13. Gardini E, Caravita L, Ottani F, Ferrini D and Galvani M. [Coronary care units: who to admit and how long]. *G Ital Cardiol (Rome)*. 2007;8:5s-11s.

14. Aoki H. [Intensive care for acute myocardial infarction (coronary care unit: CCU)]. *Nihon Rinsho*. 2003;61 Suppl 5:444-50.

15. Alfredsson J, Sederholm-Lawesson S, Stenestrand U and Swahn E. Although women are less likely to be admitted to coronary care units, they are treated equally to men and have better outcome. A prospective cohort study in patients with non ST-elevation acute coronary syndromes. *Acute Card Care*. 2009;11:173-80.

16. Moledina SM, Shoaib A, Graham MM, Biondi-Zoccai G, Van Spall HGC, Kontopantelis E, Rashid M, Aktaa S, Gale CP, Weston C and Mamas MA. Association of admitting physician specialty and care quality and outcomes in non-ST-segment elevation myocardial infarction (NSTEMI): insights from a national registry. *Eur Heart J Qual Care Clin Outcomes*. 2021.

17. Mohamed MO, Rashid M, Timmis A, Clarke S, Lawson C, Michos ED, Kwok CS, De Belder M, Valgimigli M and Mamas MA. Sex differences in distribution, management and outcomes of combined ischemic-bleeding risk following acute coronary syndrome. *Int J Cardiol*. 2020.

18. Potts J, Sirker A, Martinez SC, Gulati M, Alasnag M, Rashid M, Kwok CS, Ensor J, Burke DL, Riley RD, Holmvang L and Mamas MA. Persistent sex disparities in clinical outcomes with percutaneous coronary intervention: Insights from 6.6 million PCI procedures in the United States. *PLoS One*. 2018;13:e0203325.

19. Bradley EH, Herrin J, Wang Y, McNamara RL, Webster TR, Magid DJ, Blaney M, Peterson ED, Canto JG, Pollack CV, Jr. and Krumholz HM. Racial and ethnic differences in time to acute reperfusion therapy for patients hospitalized with myocardial infarction. *Jama*. 2004;292:1563-72.

20. Rashid M, Timmis A, Kinnaird T, Curzen N, Zaman A, Shoaib A, Mohamed MO, de Belder MA, Deanfield J, Martin GP, Wu J, Gale CP and Mamas M. Racial differences in management and outcomes of acute myocardial infarction during COVID-19 pandemic. *Heart*. 2021;107:734-740.

21. Bebb O, Hall M, Fox KAA, Dondo TB, Timmis A, Bueno H, Schiele F and Gale CP. Performance of hospitals according to the ESC ACCA quality indicators and 30-day mortality for acute myocardial infarction: national cohort study using the United Kingdom Myocardial Ischaemia National Audit Project (MINAP) register. *Eur Heart J*. 2017;38:974-982.

22. Jollis JG, DeLong ER, Peterson ED, Muhlbaier LH, Fortin DF, Califf RM and Mark DB. Outcome of acute myocardial infarction according to the specialty of the admitting physician. *N Engl J Med*. 1996;335:1880-7.

23. Langhorne P and Ramachandra S. Organised inpatient (stroke unit) care for stroke: network meta-analysis. *Cochrane Database Syst Rev*. 2020;4:Cd000197.

24. Birkhead JS, Weston CF and Chen R. Determinants and outcomes of coronary angiography after non-ST-segment elevation myocardial infarction. A cohort study of the Myocardial Ischaemia National Audit Project (MINAP). *Heart*. 2009;95:1593-9.

25. Fox KA, Eagle KA, Gore JM, Steg PG and Anderson FA. The Global Registry of Acute Coronary Events, 1999 to 2009--GRACE. *Heart*. 2010;96:1095-101.

26. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, Budaj A, Avezum A, Flather MD and Fox KA. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. *Jama*. 2004;291:2727-33.

27. BCS. Out-Of-Hours Cardiovascular Care: Management of Cardiac Emergencies and Hospital In-Patients. *British Cardiovascular Society Working Group Report:* 2016; <http://www.bcs.com/documents/BCSOOHWP_Final_Report_05092016.pdf>. Accessed 22nd August 2021.

28. Kwok CS, Naneishvili T, Curry S, Aston C, Beeston M, Chell S, Cripps J, Gunter B, Jackson D, Thomas D, Jones A, Bethell H, Sandhu K, Morgan-Smith D and Beynon R. Description and development of a nurse-led cardiac assessment team. *Future Healthc J*. 2020;7:78-83.

29. Banefelt J, Lindh M, Svensson MK, Eliasson B and Tai MH. Statin dose titration patterns and subsequent major cardiovascular events in very high-risk patients: estimates from Swedish population-based registry data. *Eur Heart J Qual Care Clin Outcomes*. 2020;6:323-331.

**Figure 1: STROBE diagram to show all participant inclusion and exclusion**

Total number of NSTEMI patients in MINAP data from 2010 – 2017

(n= 369,435)

Records excluded for missing mortality data (n = 12,666)

Records excluded for admission ward data (n = 19,614)

Number of patients for Inclusion

(n= 337,155)

**Non-cardiac ward** (AMU/General medical wards)

(n= 142,876)

**Cardiac ward** (CCU/Cardiac wards)

(n=194,279)

Died in Accident and Emergency (n=294)

Missing ward data (n=2,337)

Admitted to other\* wards (n = 11,750)

Admitted to ICU (n = 5,233)

NSTEMI; non-ST-segment elevation myocardial infarction, MINAP; myocardial ischaemia national audit project, AMU; acute medical unit, CCU; cardiac care unit, ICU; intensive care unit

\*non-medical and non-cardiac wards

**Figure 2: A figure to show the correlation between the risk standardised mortality rate (adjusted for patient demographics) for each centre and the proportion of NSTEMI patients admitted to a cardiac ward.**

Chart, scatter chart

Description automatically generated

**\*RSMR** Adjusted for age, sex, ethnicity, serum creatinine level, family history of coronary heart diseases, previous coronary artery bypass graft, ischaemic ECG changes, history of heart failure, left ventricle systolic dysfunction, prior percutaneous coronary intervention (PCI), history of diabetes mellitus, hypercholesterolaemia, history of angina, history of myocardial infarction, history of cerebrovascular accident, history of peripheral vascular disease, hypertension, smoking, asthma/COPD

RSMR; risk standardised mortality rate, CI; confidence intervals

**Figure 3: Central Illustration Figure**

A picture containing diagram

Description automatically generated

NSTEMI; non-ST-segment elevation myocardial infarction, CVD; cardiovascular disease, LV; left ventricle, PCI; percutaneous coronary intervention, CABG; coronary artery bypass graft, CVA; cerebrovascular accident, ICA; invasive coronary angiogram, DAPT; dual antiplatelet therapy, MACE; major adverse cardiovascular events

\* MACE is defined as composite endpoint of in-patient mortality and reinfarction

**Table 1: Clinical characteristics**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **Non-Cardiac ward (n=142,876)** | **Cardiac ward (n=194,279)** | **P-Value** |
| Age (years) | 75 (64-84) | 70 (60-80) | <0.001 |
| Women (%) | 57,445/142,876 (40%) | 63,182/194,279 (33%) | <0.001 |
| Caucasians (%) | 122,583/132,589 (92%) | 160,472/176,053 (91%) | <0.001 |
| BMI median [IQR] | 27 (24-31) | 27 (24-31) | <0.001 |
| **Killip class** |  |  |  |
| No Heart failure | 62,375/85,715 (73%) | 105,810/130/951 (81%) | <0.001 |
| Basal crepitations | 17,659/85,715 (21%) | 17,255/130,951 (13%) | <0.001 |
| Pulmonary oedema (%) | 5,378/85,715 (6.3%) | 7,226/130,951 (5.5%) | <0.001 |
| Cardiogenic shock (%) | 303/85,715 (0.4%) | 660/130,951 (0.5%) | <0.001 |
| **GRACE score** |  |  |  |
| High risk GRACE score >140 (%) | 67,328/82,775 (81%) | 93,206/125,406 (74%) | <0.001 |
| Intermediate risk GRACE score 109-140 (%) | 12,651/82,775 (15%) | 25,259/125,406 (20%) | <0.001 |
| Low risk GRACE score <109 (%) | 2,796/82,775 (3%) | 6,941/125,406 (6%) | <0.001 |
| **Other clinical characteristics** |  |  |  |
| ECG ST changes (%) | 105,930/139,390 (76%) | 147,775/188,843 (78%) | <0.001 |
| Previous smoker (%) | 51,288/134,378 (38%) | 69,409/186,830 (37%) | <0.001 |
| Current smoker (%) | 26,037/134,378 (19%) | 44,345/186,830 (24%) | <0.001 |
| Chronic renal failure (%) | 13,743/132,773 (10%) | 14,710/184,215 (8%) | <0.001 |
| Prior percutaneous coronary intervention (%) | 17,088/132,799 (13%) | 30,115/184,234 (16%) | <0.001 |
| Diabetes (%) | 37,949/140,728 (27%) | 50,300/191,585 (26%) | <0.001 |
| CCF (%) | 12,974/132,800 (10%) | 12,892/184,199 (7%) | <0.001 |
| Hypercholesterolemia (%) | 43,238/132,019 (33%) | 73,252/182,804 (40%) | <0.001 |
| Previous MI (%) | 42,651/133,758 (32%) | 56,168/185,925 (30%) | <0.001 |
| Angina (%) | 44,210/133,000 (33%) | 57,864/183,600 (32%) | <0.001 |
| Cerebrovascular disease (%) | 16,080/133,081 (12%) | 16,467/184,390 (9%) | <0.001 |
| Peripheral vascular disease (%) | 7,332/132,161 (6%) | 10,288/183,789 (6%) | 0.54 |
| Hypertension (%) | 74,359/134,226 (55%) | 104,478/185,402 (56%) | <0.001 |
| Asthma / COPD (%) | 25,864/133,287 (19%) | 30,187/184,499 (16%) | <0.001 |
| Family history of CAD (%) | 26,043/105,843 (25%) | 50,835/161,511 (31%) | <0.001 |
| Heart rate, bpm, median (IQR) | 79 (67-93) | 76 (65-90) | <0.001 |
| Systolic blood pressure, median (IQR) | 140 (121-158) | 140 (122-158) | 0.32 |
| Moderate LVSD | 17,159/109,898 (16%) | 29,240/149,150 (20%) | <0.001 |
| Severe LVSD | 7,521/109,898 (7%) | 11,587/149,150 (8%) | <0.001 |
| Admission under Cardiologist during first 24 hours (%) | 21,512/137,246 (16%) | 146,681/188,115 (78%) | <0.001 |
| Cardiac arrest (%) | 3,447/140,174 (2.5%) | 4,454/189,140 (2.4%) | 0.05 |
| Previous CABG (%) | 12,420/133,037 (9%) | 18,279/184,379 (10%) | <0.001 |

CABG surgery; coronary artery bypass grafting surgery, PCI; percutaneous coronary intervention, MI; myocardial infarction, BMI; body mass index, GRACE: global registry of acute coronary events, ECG; electrocardiograph, CCF; congestive cardiac failure, COPD; chronic obstructive pulmonary disease, CAD; coronary artery disease, IQR; interquartile range, LVSD; left ventricular systolic dysfunction, EF; ejection fraction

**Table 2: Management strategy & crude clinical outcome**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **Non-Cardiac ward (n=142,876)** | **Cardiac ward (n=194,279)** | **P-Value** |
| **Pharmacotherapy** |  |  |  |
| Low molecular weight heparin (%) | 63,846/120,734 (53%) | 83,223/167,934 (50%) | <0.001 |
| Fondaparinux | 60,060/121,133 (50%) | 75,242/168,577 (45%) | <0.001 |
| Warfarin (%) | 8,357/120,040 (7%) | 10,366/166,921 (6%) | <0.001 |
| Unfractionated heparin | 10,643/119,617 (9%) | 32,930/166,376 (20%) | <0.001 |
| Glycoprotein 2b/3a inhibitor (%) | 2,579/122,017 (2%) | 7,426/169,024 (4%) | <0.001 |
| IV Nitrate | 13,010/119,981 (11%) | 24,094/166,887 (14%) | <0.001 |
| Furosemide (%) | 38,875/120,378 (32%) | 44,599/167,376 (27%) | <0.001 |
| Calcium channel blockers (%) | 23,969/120,179 (20%) | 33,689/167,133 (20%) | 0.16 |
| IV beta blockers (%) | 971/120,689 (0.8%) | 2,273/167,860 (1.4%) | <0.001 |
| MRA (%) | 8,339/119,730 (7%) | 12,073/165,600 (7%) | 0.001 |
| Thiazide diuretics (%) | 5,956/119,771 (5%) | 7,730/166,687 (4.6%) | <0.001 |
| Aspirin (%) | 135,989/142,413 (95%) | 188,631/193,737 (97%) | <0.001 |
| P2Y12 inhibitor (%) | 129,478/142,323 (91%) | 179,672/193,534 (93%) | <0.001 |
| Statins (%) | 115,283/141,645 (81%) | 164,792/193,178 (85%) | <0.001 |
| ACE inhibitors/ARB (%) | 110,538/141,607 (78%) | 161,248/193,311 (83%) | <0.001 |
| Beta-Blockers (%) | 110,647/140,980 (78%) | 161,757/192,558 (84%) | <0.001 |
| **Management strategy** |  |  |  |
| Radionuclide Study (%) | 3,298/123,456 (2.7%) | 3,961/164,393 (2.4%) | <0.001 |
| Exercise test | 3,030/123,897 (2%) | 7,330/168,632 (4%) | <0.001 |
| Coronary angiogram (%) | 80,147/136,934 (59%) | 144,457/184,895 (78%) | <0.001 |
| Percutaneous coronary intervention (%) | 37,361/104,436 (36%) | 82,071/157,704 (52%) | <0.001 |
| CABG (%) | 6,821/104,436 (7%) | 12,156/157,704 (8%) | <0.001 |
| Revascularization (CABG/PCI) | 44,182/104,436 (42%) | 94,227/157,704 (60%) | <0.001 |
| **Crude in-hospital clinical outcomes** |  |  |  |
| Death (%) | 8,903/142,876 (6.2%) | 5,299/194,279 (2.7%) | <0.001 |
| Cardiac mortality (%) | 6,829/142,876 (4.8%) | 4,373/194,279 (2.2%) | <0.001 |
| Reinfarction (%) | 1,229/132,239 (0.9%) | 1,572/182,182 (0.9%) | 0.05 |
| Major bleeding (%) | 2,340/139,507 (1.7%) | 2,396/190,628 (1.3%) | <0.001 |
| MACE\* (%) | 9,810/142,876 (6.9%) | 6,638/194,279 (3.4%) | <0.001 |

CABG surgery; coronary artery bypass grafting surgery, IV; intravenous, MRA; mineralocorticoid receptor antagonist, ACE; angiotensin converting enzyme inhibitor, ARB; angiotensin receptor blockers, MACE; major adverse cardiovascular events

\* MACE is defined as composite endpoint of in-patient mortality and reinfarction

**Table 3: ESC ACVC Quality indicators**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Non-Cardiac ward (n=142,876)** | **Cardiac ward (n=194,279)** | **P-Value** |
| Coronary Angiography received within 72 hours | 25,332/47,473 (53%) | 72,415/98,747 (74%) | <0.001 |
| Grace Risk score recorded in notes | N/A | N/A | N/A |
| CRUSADE risk score recorded in notes | N/A | N/A | N/A |
| LV Function recorded in notes | 65,414/109,898 (60%) | 99,975/149,150 (67%) | <0.001 |
| Adequate P2Y12 Inhibition on discharge | 129,478/142,323 (91%) | 179,672/193,534 (93%) | <0.001 |
| Fondaparinux or LMWH received | 107,386/122,714 (88%) | 140,166/170,891 (82%) | <0.001 |
| DAPT received on discharge | 125,165/142,109 (88%) | 175,886/193,337 (91%) | <0.001 |
| High intensity statin on discharge | 115,283/141,645 (81%) | 164,792/193,178 (85%) | <0.001 |
| ACE inhibitor or ARB on discharge for those with moderate and severe LVSD (%) | 20,192/24,425 (83%) | 34,887/40,703 (86%) | <0.001 |
| B-blocker on discharge for those with moderate and severe LVSD (%) | 20,009/24,363 (82%) | 35,143/40,562 (87%) | <0.001 |

ESC; European society of cardiology, Association for Acute Cardiovascular Care (ACVC), GRACE; global registry of acute coronary events, CRUSADE; can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines, LV; left ventricle, LMWH; low molecular weight heparin, DAPT; dual antiplatelet therapy, ACEi/ARB; angiotensin converting enzyme inhibitor/angiotensin receptor blockers, LVSD; left ventricular systolic dysfunction N/A; not available

\*MINAP does not record the specific type of statins, so ‘statin prescription’ was used as a surrogate for high intensity statin.

## **Table 4: Risk of in-hospital Adverse Outcomes following multivariate adjustments**

|  |  |  |  |
| --- | --- | --- | --- |
| **Clinical outcomes** | **Adjusted Odds\* ratio as compared to reference (Non-Cardiac ward)** | **P-value** | **95% CI** |
| **Primary Outcomes** |  | | |
| Death (n of observations = 337,155) | OR: 0.75 | <0.001 | 0.70-0.81 |
| MACE# (n of observations = 337,155) | OR: 0.85 | <0.001 | 0.79-0.90 |
| **Secondary Outcomes** |  | | |
| Cardiac Death (n of observations = 337,155) | OR: 0.84 | <0.001 | 0.78-0.91 |
| Major bleeding (n of observations = 337,155) | OR: 0.76 | <0.001 | 0.71-0.83 |

**\*** Adjusted for age, sex, ethnicity, heart rate, blood pressure, serum creatinine level, family history of coronary heart diseases, previous coronary artery bypass graft surgery, ischaemic ECG changes, history of heart failure, left ventricle systolic dysfunction, prior percutaneous coronary intervention (PCI), history of diabetes mellitus, hypercholesterolaemia, history of angina, history of myocardial infarction, history of cerebrovascular accident, history of peripheral vascular disease, hypertension, smoking, asthma/COPD, prescription of low molecular weight heparin, warfarin, un-fraction heparin, GP 2b/3a inhibitor, IV nitrate, furosemide, aldosterone antagonist, fondaparinux, beta blockers, angiotensin converting enzyme inhibitor/angiotensin receptor blockers, aspirin, P2Y12 inhibitor, statins, cardiac arrest, coronary angiogram, PCI, CABG surgery, type of centre (catheter laboratory status), admission under a cardiologist in the first 24 hours, hospital and year on imputed data.

CABG surgery; coronary artery bypass grafting surgery

MACE; major adverse cardiovascular events

# MACE is defined as composite endpoint of in-patient mortality and reinfarction

**Table 5: Factors associated with admission to a cardiac ward**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Odds Ratio** | **95% CI (lower)** | **95% CI (upper)** | **P-Value** |
| Age | 0.99 | 0.99 | 0.99 | <0.001 |
| Sex (female) | 0.88 | 0.87 | 0.90 | <0.001 |
| **Ethnicity (White reference)** |  |  |  |  |
| Black | 0.96 | 0.87 | 1.05 | 0.36 |
| Asian | 0.96 | 0.92 | 1.00 | 0.07 |
| Other Non-White ethnicities | 1.00 | 0.93 | 1.08 | 0.98 |
| Ischaemic ECG changes | 1.20 | 1.18 | 1.23 | <0.001 |
| **LV function (Normal – reference)** |  |  |  |  |
| Moderate impairment | 1.25 | 1.21 | 1.28 | <0.001 |
| Severe impairment | 1.21 | 1.16 | 1.27 | <0.001 |
| Heart Failure | 0.89 | 0.86 | 0.91 | <0.001 |
| Diabetes | 0.96 | 0.94 | 0.99 | 0.001 |
| Hypercholesterolemia | 1.09 | 1.07 | 1.12 | <0.001 |
| Hypertension | 1.04 | 1.02 | 1.06 | <0.001 |
| History of CVA | 0.88 | 0.85 | 0.90 | <0.001 |
| History of PVD | 0.94 | 0.91 | 0.98 | 0.002 |
| History of AMI | 0.94 | 0.92 | 0.96 | <0.001 |
| History of angina | 0.97 | 0.95 | 0.99 | 0.02 |
| Family history of coronary heart disease | 1.07 | 1.04 | 1.09 | <0.001 |
| Previous PCI | 1.19 | 1.16 | 1.22 | <0.001 |
| Previous CABG surgery | 1.05 | 1.01 | 1.09 | 0.002 |
| **Smoking (never smoked – reference)** |  |  |  |  |
| Ex-smoker | 1.05 | 1.03 | 1.07 | <0.001 |
| Current smoker | 1.04 | 1.02 | 1.07 | 0.001 |
| Asthma/COPD | 0.90 | 0.88 | 0.92 | <0.001 |
| Admissions as a cardiac arrest | 1.03 | 0.97 | 1.09 | 0.31 |
| Admitted under Cardiologist (first 24 hours of care) | 18.2 | 17.9 | 18.6 | <0.001 |
| Admitted to a centre with catheter laboratory facilities | 0.96 | 0.94 | 0.98 | <0.001 |

CHD; coronary heart disease, CABG surgery; coronary artery bypass graft surgery, LV; left ventricle, PCI; percutaneous coronary intervention, AMI; acute myocardial infarction, PVD; peripheral vascular disease, CVA; cerebrovascular accident, COPD; chronic obstructive pulmonary disease, ECG; electrocardiograph

**Supplementary Table 1: Clinical characteristics by individual subgroups**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Non-Cardiac ward (n=142,876)** | **Cardiac ward, excluding CCU (n=60,070)** | **CCU (n=134,209)** | **P-Value** |
| Age (years) | 75 (64-84) | 71 (60-80) | 70 (60-80) | <0.001 |
| Women (%) | 57,445/142,876 (40%) | 19,888/60,070 (33%) | 43,294/134,209 (32%) | <0.001 |
| Caucasians (%) | 122,583/132,589 (92%) | 48,808/52,548 (93%) | 111,664/123,505 (90%) | <0.001 |
| BMI median [IQR] | 27 (24-31) | 27 (24-31) | 27 (24-31) | <0.001 |
| **Killip class** |  |  |  |  |
| No Heart failure | 62,375/85,715 (73%) | 34,374/41,604 (83%) | 71,436/89,347 (80%) | <0.001 |
| Basal crepitations | 17,659/85,715 (21%) | 5,557/41,604 (13%) | 11,698/89,347 (13%) | <0.001 |
| Pulmonary oedema (%) | 5,378/85,715 (6.3%) | 1,594/41,604 (3.8%) | 5,632/89,347 (6.3%) | <0.001 |
| Cardiogenic shock (%) | 303/85,715 (0.4%) | 79/41,604 (0.2%) | 581/89,347 (0.7%) | <0.001 |
| **GRACE score** |  |  |  |  |
| High risk GRACE score >140 (%) | 67,328/82,775 (81%) | 28,703/39,559 (73%) | 64,503/85,847 (75%) | <0.001 |
| Intermediate risk GRACE score 109-140 (%) | 12,651/82,775 (15%) | 8,832/39,229 (21%) | 16,877/85,847 (20%) | <0.001 |
| Low risk GRACE score <109 (%) | 2,796/82,775 (3%) | 2,474/39,559 (6%) | 4,467/85,847 (5%) | <0.001 |
| **Other clinical characteristics** |  |  |  |  |
| ECG ST changes (%) | 105,930/139,390 (76%) | 43,859/58,421 (75%) | 103,916/130,422 (80%) | <0.001 |
| Previous smoker (%) | 51,288/134,378 (38%) | 22,252/57,588 (39%) | 47,157/129,242 (36%) | <0.001 |
| Current smoker (%) | 26,037/134,378 (19%) | 13,343/57,588 (23%) | 31,002/129,242 (24%) | <0.001 |
| Chronic renal failure (%) | 13,743/132,773 (10%) | 4,485/56,446 (8%) | 10,225/127,769 (8%) | <0.001 |
| Prior percutaneous coronary intervention (%) | 17,088/132,799 (13%) | 9,587/56,683 (17%) | 20,528/127,551 (16%) | <0.001 |
| Diabetes (%) | 37,949/140,728 (27%) | 34,761/132,621 (26%) | 15,539/58,964 (26%) | <0.001 |
| CCF (%) | 12,974/132,800 (10%) | 8,846/127,748 (7%) | 4,046/56,451 (7%) | <0.001 |
| Hypercholesterolemia (%) | 43,238/132,019 (33%) | 23,405/55,889 (42%) | 49,847/126,915 (39%) | <0.001 |
| Previous MI (%) | 42,651/133,758 (32%) | 17,465/56,632 (31%) | 38,703/129,293 (30%) | <0.001 |
| Angina (%) | 44,210/133,000 (33%) | 18,232/55,874 (33%) | 39,632/127,726 (31%) | <0.001 |
| Cerebrovascular disease (%) | 16,080/133,081 (12%) | 5,481/56,529 (10%) | 10,986/127,861 (9%) | <0.001 |
| Peripheral vascular disease (%) | 7,332/132,161 (6%) | 3,469/56,455 (6%) | 6,819/127,334 (5%) | 0.54 |
| Hypertension (%) | 74,359/134,226 (55%) | 32,644/56,711 (58%) | 71,834/128,691 (56%) | <0.001 |
| Asthma / COPD (%) | 25,864/133,287 (19%) | 9,593/56,523 (17%) | 20,594/127,976 (16%) | <0.001 |
| Family history of CAD (%) | 26,043/105,843 (25%) | 16,695/49,142 (34%) | 34,140/112,369 (30%) | <0.001 |
| Heart rate, bpm, median (IQR) | 79 (67-93) | 75 (65-88) | 77(66-90) | <0.001 |
| Systolic blood pressure, median (IQR) | 140 (121-158) | 140 (123-158) | 139 (121-158) | 0.32 |
| Moderate LVSD | 17,159/109,898 (16%) | 7,999/44,332 (18%) | 21,241/104,818 (20%) | <0.001 |
| Severe LVSD | 7,521/109,898 (7%) | 2,854/44,332 (6%) | 8,733/104,818 (8%) | <0.001 |
| Admission under Cardiologist during first 24 hours (%) | 21,512/137,246 (16%) | 47,999/57,698 (83%) | 98,682/130,417 (76%) | <0.001 |
| Cardiac arrest (%) | 3,447/140,174 (2.5%) | 730/57,183 (1.3%) | 3,724/131,957 (2.8%) | 0.05 |
| Previous CABG (%) | 12,420/133,037 (9%) | 5,602/56,689 (10%) | 12,677/127,690 (10%) | <0.001 |

CABG surgery; coronary artery bypass grafting surgery, PCI; percutaneous coronary intervention, MI; myocardial infarction, BMI; body mass index, GRACE: global registry of acute coronary events, ECG; electrocardiograph, CCF; congestive cardiac failure, COPD; chronic obstructive pulmonary disease, CAD; coronary artery disease, IQR; interquartile range, LVSD; left ventricular systolic dysfunction, EF; ejection fraction, CCU; cardiac care unit

**Supplementary Table 2: Management strategy & crude clinical outcome by individual subgroups**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Variables** | **Non-Cardiac ward (n=142,876)** | **Cardiac ward, excluding CCU (n=60,070)** | **CCU (n=134,209)** | **P-Value** |
| **Pharmacotherapy** |  |  |  |  |
| Low molecular weight heparin (%) | 63,846/120,734 (53%) | 23,797/48,020 (50%) | 59,426/119,914 (50%) | <0.001 |
| Fondaparinux | 60,060/121,133 (50%) | 20,932/48,046 (44%) | 54,310/120,531 (45%) | <0.001 |
| Warfarin (%) | 8,357/120,040 (7%) | 3,052/47,472 (6%) | 7,314/119,449 (6%) | <0.001 |
| Unfractionated heparin | 10,643/119,617 (9%) | 13,031/47,346 (28%) | 19,889/119,030 (17%) | <0.001 |
| Glycoprotein 2b/3a inhibitor (%) | 2,579/122,017 (2%) | 1,898/48,396 (4%) | 5,528/120,628 (5%) | <0.001 |
| IV Nitrate | 13,010/119,981 (11%) | 5,355/47,379 (11%) | 18,739/119,508 (16%) | <0.001 |
| Furosemide (%) | 38,875/120,378 (32%) | 12,683/47,668 (26%) | 31,916/119,708 (27%) | <0.001 |
| Calcium channel blockers (%) | 23,969/120,179 (20%) | 10,287/47,553 (22%) | 23,402/119,580 (20%) | 0.16 |
| IV beta blockers (%) | 971/120,689 (0.8%) | 397/47,929 (0.8%) | 1,876/119,932 (1.6%) | <0.001 |
| MRA (%) | 8,339/119,730 (7%) | 3,495/47,111 (7%) | 8,578/118,489 (7%) | 0.002 |
| Thiazide diuretics (%) | 5,956/119,771 (5%) | 2,308/47,423 (4.9%) | 5,422/119,264 (4.6%) | <0.001 |
| Aspirin (%) | 135,989/142,413 (95%) | 58,376/59,957 (97%) | 130,255/133,780 (97%) | <0.001 |
| P2Y12 inhibitor (%) | 129,478/142,323 (91%) | 55,522/59,802 (93%) | 124,150/133,732 (93%) | <0.001 |
| Statins (%) | 115,283/141,645 (81%) | 52,636/59,853 (88%) | 112,156/133,325 (84%) | <0.001 |
| ACE inhibitors/ARB (%) | 110,538/141,607 (78%) | 49,286/59,802 (83%) | 111,962/133,509 (84%) | <0.001 |
| Beta-Blockers (%) | 110,647/140,980 (78%) | 49,843/59,682 (84%) | 111,914/132,876 (84%) | <0.001 |
| **Management strategy** |  |  |  |  |
| Radionuclide Study (%) | 3,298/123,456 (2.7%) | 1,215/48,985 (2.5%) | 2,746/115,408 (2.4%) | <0.001 |
| Exercise test | 3,030/123,897 (2%) | 2,429/49,704 (5%) | 4,901/118,928 (4%) | <0.001 |
| Coronary angiogram (%) | 80,147/136,934 (59%) | 45,331/57,147 (79%) | 99,126/127,748 (78%) | <0.001 |
| Percutaneous coronary intervention (%) | 37,361/104,436 (36%) | 28,627/52,642 (54%) | 53,444/105,062 (51%) | <0.001 |
| CABG (%) | 6,821/104,436 (7%) | 3,675/52,642 (7%) | 8,841/105,062 (8%) | <0.001 |
| Revascularization (CABG/PCI) | 44,182/104,436 (42%) | 32,302/52,642 (61%) | 61,925/105,062 (59%) | <0.001 |
| **Crude in-hospital clinical outcomes** |  |  |  |  |
| Death (%) | 8,903/142,876 (6.2%) | 1,134/60,070 (1.9%) | 4,165/134,209 (3.1%) | <0.001 |
| Cardiac mortality (%) | 6,829/142,876 (4.8%) | 890/60,070 (1.5%) | 3,483/134,209 (2.6%) | <0.001 |
| Reinfarction (%) | 1,229/132,239 (0.9%) | 489/55,469 (0.9%) | 1,083/126,713 (0.9%) | 0.13 |
| Major bleeding (%) | 2,340/139,507 (1.7%) | 871/58,793 (1.5%) | 1,525/131,835 (1.2%) | <0.001 |
| MACE\* (%) | 9,810/142,876 (6.9%) | 1,579/60,070 (2.6%) | 5,059/134,209 (3.8%) | <0.001 |

CABG surgery; coronary artery bypass grafting surgery, IV; intravenous, MRA; mineralocorticoid receptor antagonist, ACE; angiotensin converting enzyme inhibitor, ARB; angiotensin receptor blockers, MACE; major adverse cardiovascular events, CCU; coronary care unit

\* MACE is defined as composite endpoint of in-patient mortality and reinfarction

**Supplementary Table 3: ESC ACVC Quality indicators by individual subgroups**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Non-Cardiac ward (n=142,876)** | **Cardiac ward, excluding CCU (n=60,070)** | **CCU (n=134,209)** | **P-Value** |
| Coronary Angiography received within 72 hours | 25,332/47,473 (53%) | 26,863/37,474 (72%) | 46,552/62,986 (74%) | <0.001 |
| Grace Risk score recorded in notes | N/A | N/A | N/A | N/A |
| CRUSADE risk score recorded in notes | N/A | N/A | N/A | N/A |
| LV Function recorded in notes | 65,414/109,898 (60%) | 28,870/44,332 (65%) | 71,105/104,818 (68%) | <0.001 |
| Adequate P2Y12 Inhibition on discharge | 129,478/142,323 (91%) | 55,522/59,802 (93%) | 124,150/133,732 (93%) | <0.001 |
| Fondaparinux or LMWH received | 107,386/122,714 (88%) | 39,126/48,893 (80%) | 101,040/121,998 (83%) | <0.001 |
| DAPT received on discharge | 125,165/142,109 (88%) | 54,423/59,768 (91%) | 121,463/133,569 (91%) | <0.001 |
| High intensity statin on discharge | 115,283/141,645 (81%) | 52,636/59,853 (88%) | 112,156/133,325 (84%) | <0.001 |
| ACE inhibitor or ARB on discharge for those with moderate and severe LVSD (%) | 20,192/24,425 (83%) | 9,201/10,840 (85%) | 25,686/29,863 (86%) | <0.001 |
| B-blocker on discharge for those with moderate and severe LVSD (%) | 20,009/24,363 (82%) | 9,342/10,821 (86%) | 25,801/29,741 (87%) | <0.001 |

ESC; European society of cardiology, Association for Acute Cardiovascular Care (ACVC), GRACE; global registry of acute coronary events, CRUSADE; can rapid risk stratification of unstable angina patients suppress adverse outcomes with early implementation of the ACC/AHA guidelines, LV; left ventricle, LMWH; low molecular weight heparin, DAPT; dual antiplatelet therapy, ACEi/ARB; angiotensin converting enzyme inhibitor/angiotensin receptor blockers, LVSD; left ventricular systolic dysfunction N/A; not available

\*MINAP does not record the specific type of statins, so ‘statin prescription’ was used as a surrogate for high intensity statin.

**Supplementary Table 4: Adjusted clinical outcomes, subgroup analysis**

|  |  |  |
| --- | --- | --- |
|  | **Admitted to cardiac ward vs CCU (reference group)** | **Admitted to cardiac ward vs non-cardiac ward (reference group)** |
| **Primary Outcomes** |  | |
| Mortality (n=337,155) | OR:0.80, 95% CI: 0.73-0.87, P<0.001 | OR: 0.64, 95% CI: 0.58-0.70, P<0.001 |
| MACE# (n of observations = 337,155) | OR: 0.92, 95% CI: 0.86–0.99, P = 0.02 | OR: 0.80, 95% CI: 0.74-0.86, P<0.001 |
| **Secondary Outcomes** |  | |
| Cardiac Mortality (n=337,155) | OR: 0.75, 95% CI: 0.68 -0.82, P<0.001 | OR: 0.68, 95% CI: 0.62-0.75, P<0.001 |
| Major Bleeding (n=337,155) | OR: 1.39, 95% CI:1.28 – 1.52, P<0.001 | OR: 0.96, 95% CI: 0.87-1.06, P = 0.42 |

**\*** Adjusted for age, sex, ethnicity, heart rate, blood pressure, serum creatinine level, family history of coronary heart diseases, previous coronary artery bypass graft surgery, ischaemic ECG changes, history of heart failure, left ventricle systolic dysfunction, prior percutaneous coronary intervention (PCI), history of diabetes mellitus, hypercholesterolaemia, history of angina, history of myocardial infarction, history of cerebrovascular accident, history of peripheral vascular disease, hypertension, smoking, asthma/COPD, prescription of low molecular weight heparin, warfarin, un-fraction heparin, GP 2b/3a inhibitor, IV nitrate, furosemide, aldosterone antagonist, fondaparinux, beta blockers, angiotensin converting enzyme inhibitor/angiotensin receptor blockers, aspirin, P2Y12 inhibitor, statins, cardiac arrest, coronary angiogram, PCI, CABG surgery, type of centre (catheter laboratory status), admission under a cardiologist in the first 24 hours, hospital and year on imputed data.

CABG surgery; coronary artery bypass grafting surgery, AMU; acute medical unit, CCU; cardiac care unit


MACE; major adverse cardiovascular events

# MACE is defined as composite endpoint of in-patient mortality and reinfarction

**Supplement Figure 1: The proportion of NSTEMI patients between 2010-2017 admitted by specialty of ward**

NSTEMI; non-ST-segment elevation myocardial infarction

**Supplement Figure 2: A figure to show the variation in the proportion of NSTEMI patients admitted to a cardiac ward by hospital.**



NSTEMI; non-ST-segment elevation myocardial infarction

**Supplement Figure 3: A figure to show the correlation between the risk standardised mortality rate (adjusted for patient demographics) for each centre and the proportion of NSTEMI patients admitted to a cardiac ward (CCU patients excluded)**

Chart, scatter chart

Description automatically generated

**\*RSMR1** Adjusted for age, sex, ethnicity, serum creatinine level, family history of coronary heart diseases, previous coronary artery bypass graft, ischaemic ECG changes, history of heart failure, left ventricle systolic dysfunction, prior percutaneous coronary intervention (PCI), history of diabetes mellitus, hypercholesterolaemia, history of angina, history of myocardial infarction, history of cerebrovascular accident, history of peripheral vascular disease, hypertension, smoking, asthma/COPD

RSMR1; risk standardised mortality rate, CI; confidence intervals, CCU; cardiac care unit